AbbVie (ABBV 0.54%) is one of the globe's top drugmakers and it's quickly become a staple in dividend investors' portfolios since separating from Abbott Labs in 2013.
Big drug companies, such as AbbVie, Johnson & Johnson (JNJ -2.13%), and Amgen (AMGN 0.05%), offer investors predictable, dividend-boosting revenue regardless of the economy's whims and whispers. But investors are correct to wonder if AbbVie's dividend can be sustained in light of billions in at-risk revenue tied to the future patent expiration on its top selling drug, Humira.
In the following slideshow you'll see whether I think AbbVie's dividend is safe and gain insight into how AbbVie matches up with industry peers.
